TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04506372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perioperative withdrawal of angiotensin converting enzyme inhibitors and angiotenin receptor blockers
Description: Withdrawal from 24 hours before surgery until 24-48 hours after surgery. The ACEI/ARB medication is resumed on the second or third day after surgery, as soon as the clinical condition allows based on judgement by the attending physician.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Blood draw
Description: Blood will be drawn to measure creatinin and troponin: once before surgery, on the first and second postoperative day, and within 4-8 weeks after surgery

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood draw
Description: Blood will be drawn to measure creatinin and troponin: once before surgery, on the first and second postoperative day, and within 4-8 weeks after surgery

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diary to register drug adherence
Description: To register medication adherence, patients will be asked to fill out their medication intake (of ACEI/ARB) in a diary from a week before surgery until surgery.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diary to register drug adherence
Description: To register medication adherence, patients will be asked to fill out their medication intake (of ACEI/ARB) in a diary from a week before surgery until surgery.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Quality of life questionnaire
Description: Patients are asked to fill out a quality of life questionnaire (EQ-5D) before surgery and at three months after surgery

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quality of life questionnaire
Description: Patients are asked to fill out a quality of life questionnaire (EQ-5D) before surgery and at three months after surgery

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: WHODAS questionnaire
Description: Patients are asked to fill out a questionnaire about disabilities (WHO Disability Assessment Schedule 2.0) before surgery and at three months after surgery

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WHODAS questionnaire
Description: Patients are asked to fill out a questionnaire about disabilities (WHO Disability Assessment Schedule 2.0) before surgery and at three months after surgery
Study: NCT01389817

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Near-infrared light-emitting diode (NIR-LED) therapy (Med Light 630 PRO (Medical Devices Inc.))
Description: Subjects will be exposed to light emitted from a Med Light 630 PRO (Medical Devices Inc.) at a wavelength of 630 nm (+/-15nm) with an exposure of 4 J/cm2. This is accomplished by applying the 50 mW/cm2 LED-generated light to the closed study eye for 80 seconds. Treatments involve application of the LED-generated light for 80 seconds, twice daily.
Study: NCT00105469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AzaSite
Description: AzaSite ophthalmic solution; one topical drop to the infected eye or eyes twice daily (in the morning and at bedtime) on Days 1 and 2 followed by once daily (in the morning between 7 and 10am) on Days 3 through 5.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tobramycin
Description: Tobramycin ophthalmic solution; one topical drop to the infected eye or eyes four times daily at 4 to 6 hour intervals (first dose in the morning between 7 and 10am) for 5 days.
Study: NCT02532491

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: Initial dose: 10 mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: Initial dose: 2 mg.
Study: NCT02720471

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Locoregional anesthesia
Description: classical analgesia by ultrasound guidance by blocks of the femoral and cutaneous nerves side of the thigh

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peroperative infiltration of local anesthetics
Description: peroperative infiltration of local anesthetics
Study: NCT02467868

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MYL-1401H
Description: During each chemotherapy cycle MYL-1401H (6 mg) is administered s.c. 24 hours after chemotherapy.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Neulasta
Description: During each chemotherapy cycle Neulasta (6 mg) is administered s.c. 24 hours after chemotherapy.
Study: NCT04344509

Intervention type: OTHER
Intervention: Bacterial species isolated
Description: in the respiratory specimen

Intervention type: OTHER
Intervention: Bacterial species isolated
Description: in the respiratory specimen
Study: NCT03833245

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Navigation
Description: The patient navigation (PN) intervention will initiate following participant recruitment. It is important to note that PN sessions do not strictly coincide with specific weeks of pregnancy since the women can be recruited up to ≤25 weeks of gestation. The prenatal portion of the intervention includes 10 sessions delivered within approximately 14 weeks. The postnatal portion of the intervention will be delivered as 4 sessions over 8 weeks. Women who complete the intervention before delivery will receive regular calls/texts until delivery wherein the navigator will encourage and reinforce abstinence and treatment retention. All contact will be reported by staff in a patient contact log developed for the study that will be used to quantify level of patient contact.
Study: NCT02183194

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lutonix Paclitaxel Drug Coated Balloon
Study: NCT04922775

Intervention type: PROCEDURE
Group type: OTHER
Intervention: conventional taping
Description: Participants will accept conventional taping before muscle fatigue exercise.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: conventional taping
Description: Participants will accept conventional taping before muscle fatigue exercise.
Study: NCT02731846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate 100 mcg + Vilanterol 25 mcg
Description: Dry white powder delivered via ELLIPTA inhaler (2 strips with 30 blisters each, first containing fluticasone furoate 100 mcg per blister and second containing Vilanterol 25 mcg per blister), administered as one inhalation of FF/VI (100/25 mcg) once-daily in the morning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umeclidinium 62.5 mcg
Description: Dry white powder delivered via ELLIPTA inhaler (1 strip with 30 blisters containing Umeclidinium 62.5 mcg, administered as one inhalation once-daily in the morning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umeclidinium 62.5 mcg
Description: Dry white powder delivered via ELLIPTA inhaler (1 strip with 30 blisters containing Umeclidinium 62.5 mcg, administered as one inhalation once-daily in the morning

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placebo ELLIPTA inhaler
Description: Placebo will be administered via ELLIPTA inhaler. Dry white powder administered as one inhalation each morning (1 strip with 30 blisters containing placebo)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placebo ELLIPTA inhaler
Description: Placebo will be administered via ELLIPTA inhaler. Dry white powder administered as one inhalation each morning (1 strip with 30 blisters containing placebo)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol/Salbutamol
Description: Albuterol/salbutamol will be administered via metered-dose inhaler (MDI) with a spacer as needed throughout the study as a rescue medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol/Salbutamol
Description: Albuterol/salbutamol will be administered via metered-dose inhaler (MDI) with a spacer as needed throughout the study as a rescue medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol/Salbutamol
Description: Albuterol/salbutamol will be administered via metered-dose inhaler (MDI) with a spacer as needed throughout the study as a rescue medication
Study: NCT03817970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granisetron
Description: An antiemetic regimen containing granisetron 2 mg oral or IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: An antiemetic regimen containing ondansetron 8 mg oral or IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron
Description: An antiemetic regimen containing palonosetron 0.25 mg IV.
Study: NCT04587505

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural anesthesia with light general anesthesia
Description: Epidural anaesthesia: mixture of ropivacaine 6.5 mg/ ml and fentanyl 8.3 μg/ml. Light general anesthesia: isoflurane in mixture of 50/50 of nitrous oxide and oxygen to achieve Minimum alveolar concentration between 0.6 and 0.8.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative epidural analgesia
Description: Before the end of operation was given 4 ml of the mixture of ropivacaine 4.4 mg/ml and morphine 0.8mg/ ml. Epidural analgesia was continued for next 24 hours with a mixture of ropivacaine 2.2 mg/ml and morphine 0.4 mg/ml.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia
Description: Maintaining general anesthesia: nitrous oxide and oxygen in mixture 50/50 and isoflurane to achieve minimum alveolar concentration between 0.8 and 1. Fentanyl loading dose: 6-8 μg/kg. Additional fentanyl doses were given incrementally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continuous intravenous analgesia
Description: Tramadol 100 mg in the first hour followed by tramadol 300 mg continuously for the next 24 hours.
Study: NCT01057459

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03978728

Intervention type: DEVICE
Intervention: Extra-corporeal membrane oxygenation
Description: Cardiovascular shock patients received extra-corporeal membrane oxygenation suppot.
Study: NCT00537212

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The South Beach Diet
Description: Subjects will receive dietary counselling aimed at reducing simple carbohydrates and increasing weight loss. Subjects also receive a copy of The South Beach Diet.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The Ornish Diet
Description: Subjects will receive dietary counselling aimed to reduce fat consumption and increase weight loss. Subjects also receive a copy of The Ornish Diet book.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control Group
Description: This group will receive phototherapy alone. They will not be counselled or give literature on a particular diet.
Study: NCT05122468

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Connective tissue Harvest and CAF
Description: A connective tissue graft will be harvested from the palate as a free gingival graft, which will be de-epithelialized with a 15-c blade(Zucchelli et al. 2010) before opening of the opaque envelopes, which contains the allocation concealment. The dimensions of the graft achieve 3 to 5 mm mesial and distal from the lateral teeth with an ideal thickness about 1 to 1.5 mm. Donor tissue will be taken at premolar and molar level. In control sites, the graft will be adapted to cover each exposed root to the CEJ, and stabilized with either 6-0 resorbable sutures (with the knot placed under the papillary area) or a non-resorbable suture with the knot on the palatal side. For suturing of the graft, interrupted sutures or sling sutures (anchored to periosteum apical to the graft and hanging around the neck of the experimental teeth) may be used.
Study: NCT04922775

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Chinese medicine technique taping
Description: Participants will accept Chinese medicine technique taping before muscle fatigue exercise.
Study: NCT05122468

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Connective tissue Harvest and Tunnel
Description: A connective tissue graft will be harvested from the palate as a free gingival graft, which will be de-epithelialized with a 15-c blade(Zucchelli et al. 2010) before opening of the opaque envelopes, which contains the allocation concealment. The dimensions of the graft achieve 3 to 5 mm mesial and distal from the lateral teeth with an ideal thickness about 1 to 1.5 mm. Donor tissue will be taken at premolar and molar level.~In test sites, the graft should be slid through the tunnel. To accomplish the adequate position of the graft into the tunnel, 2 sutures are first placed, 1 at the most mesial and the other at the most distal aspect of the tunnel. The needles should pass underneath the tunnel and exit through the largest or most central gingival recession, the one through which the grafting tissue will be introduced. With these 2 sutures already inside the tunnel, the graft is bitten on both ends with vertical mattress sutures.
Study: NCT03856619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TERIFLUNOMIDE HMR1726
Description: Pharmaceutical form: Tablet~Route of administration: Oral
Study: NCT00949949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV
Study: NCT00478595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimonabant
Description: Tablet, oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Rimonabant)
Description: Tablet, oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Anti-diabetic monotherapy
Description: Previous treatment with Sulfonylurea or α-glucosidase inhibitor continued at stable dose during the study period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-diabetic monotherapy
Description: Previous treatment with Sulfonylurea or α-glucosidase inhibitor continued at stable dose during the study period
Study: NCT02543606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomelone
Description: powder for injection/ infusion Esomeprazole 40mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomelone
Description: powder for injection/ infusion Esomeprazole 40mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nexium
Description: powder for injection/ infusion Esomeprazole 40mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nexium
Description: powder for injection/ infusion Esomeprazole 40mg
Study: NCT04252391

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Perineural electrical dry needling
Description: Standard care plus use of perineural electrical dry needling involving use of a monofilament needle of 15 or 30 mm length, 0.25 mm diameter will be placed utilizing the therapist's dominant hand following palpation of correct needle location. An electrical stimulation unit will be used to conduct an electrical impulse. The unit used will be an ES-130 by ITO (Japan) using a DC 9V battery producing an asymmetrical biphasic waveform. The unit has 6 available leads with alligator clamps, connecting to needle shafts. Parameters of PNED will include intensity set at a strong yet comfortable setting according to patient feedback. Treatment duration will be 15 minutes. Treatment frequency will be set to Medium at level 8 (80 Hz). Parameters will be set to elicit a sensory response.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: cervical or thoracic manipulation or mobilization, muscle stretching, muscle strengthening, electrical trigger point dry needling , soft tissue release and prescribed therapeutic exercises .
Study: NCT03001791

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Excisional biopsy with Er:YAG laser
Description: Excisional biopsy of fibrous hyperplasia in the buccal mucosa in local anesthesia with Er:YAG laser (Lite TouchTM, Synergon Dental Lasers, Light instruments Ltd., Yokneam Elite, Israel), λ = 2940nnm. Soft tissue biopsy mode with water cooling, frequency 35 Hz, pulse duration 250-390 µsec, pulse energy of 200 mJ, power 7 Watt . Cylindrical sapphire tip, 400 µm in diameter, without contact to the tissue.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Excisional biopsy with CO2 laser
Description: Excisional biopsy of fibrous hyperplasia in the buccal mucosa in local anesthesia with CO2 laser (Spectra DENTA Surgical Carbon Dioxide Laser, MAX Engineering Ltd., Gyeonggi-Do, Korea), λ = 10'600nnm. cf mode (frequency 140 Hz, pulse duration 400 µsec, pulse energy 33 mJ,a power 4.62 watts). Laser beam with a spot size of 0.2 mm, non-contact mode.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Excisional biopsy with scalpel
Description: Excisional biopsy of fibrous hyperplasia in the buccal mucosa in local anesthesia with scalpel (blade 15C). Polyamide sutures (Seralon 5-DS15, Serag Wiessner KG, Naila, Germany).
Study: NCT01609491

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: phenylephrine
Description: If the mean arterial pressure drops below 20% of the baseline value and/or below 90 mmHg, a syringe pump with phenylephrine or norepinephrine (depending on randomisation) will be started. The anaesthetist will be blinded for the type of vasopressor. Concentrations phenylephrine (20 µg /ml) of Norepinephrine (10 µg/ml) will be used in the syringes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: norepinephrine
Description: If the mean arterial pressure drops below 20% of the baseline value and/or below 90 mmHg, a syringe pump with norepinephrine (depending on randomisation) will be started. The anaesthetist will be blinded for the type of vasopressor. Concentrations Norepinephrine (10 µg/ml) will be used in the syringes
Study: NCT04594889

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: angioplasty
Description: Balloon releasing a drug inflated in the target vessel

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: angioplasty
Description: Balloon releasing a drug inflated in the target vessel
Study: NCT00420212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BG00012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BG00012

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03998995

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Immersive Virtual Reality
Description: An Oculus Rift VR Headset and a set of Oculus Touch Controllers was used as interactivity device. Two scenarios of IVR rehabilitation game were offered to the patients: 1) Archery based on behind-the-neck overhead press, using a quiver on the user back to encourage bending their arm and firing the arrow to help with stretching exercises and 2) Climbing based on an overhead arm raise exercise.~Each child will took part in a single IVR trial during their rehabilitation care with the physiotherapist, supported by IP, the games expert/researcher. Timing of participation was approximately 15 minutes of trial with each scenario of game. A short interview was conducted with each child and their parent (together) after each trial, and a focus group was conducted with the clinical staff.
Study: NCT03363789

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Brisement injection
Description: An injection of Lidocaine into the tendon sheath to break up adhesions that could be causing the condition.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: Patients will receive a prescription for physical therapy.
Study: NCT01118585

Intervention type: PROCEDURE
Group type: OTHER
Intervention: TIF Procedure
Description: The TIF procedure results in the creation of an esophago-gastric fundoplication extending up to 4 cm above the Z-line and 270 degrees around the esophagus.
Study: NCT00944476

Intervention type: PROCEDURE
Intervention: Fat-free MRI images utilizing standard magnetization, Questionnaire before the MRI exam
Description: In addition to the traditional MRI exam for clinical use, a fat-free MRI based on standard magnetization transfer magnetic resonance imaging will be acquired. Pts will spend 20 extra minutes and 20 minutes total for volunteers in the MRI scanner. Patients/volunteers will complete the MR Screening Questionnaire before the MRI exam.
Study: NCT02647203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Self-administered fluoridated dentifrices
Description: Elderly participants will be instructed to self administer toothpastes, twice per day. Toothpastes will be provided.
Study: NCT03837301

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NESS-EFTR with sentinel lymph node navigation
Description: Non-exposure Simple Suturing Endoscopic Full-Thickness Resection with sentinel lymph node navigation (basin dissection) for early gastric cancer patients
Study: NCT00611416

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: green tea
Description: different catechin combinations

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: green tea
Description: different catechin combinations

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: green tea
Description: different catechin combinations

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mix of catechins and caffeine
Description: 3 tablet a day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: EGCG
Description: 3 tablets a day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: EGC
Description: 3 tablets a day

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine
Description: 3 tablets a day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 tablets a day
Study: NCT03517735

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EasyTiva (algorithm is the property of Medsteer SAS)
Description: Propofol and Remifentanil are administered automatically using a closed-loop system. Bispectral index is used as the input signal and an algorithm defines the appropriate concentrations of propofol and remifentanil. Adequate postoperative sedation is defined by a bispectral index between 55 and 75.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: The dosage is modified automatically by the device or according to the new medical prescription.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: The dosage is modified automatically by the device or according to the new medical prescription.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: The dosage is modified automatically by the device or according to the new medical prescription.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: The dosage is modified automatically by the device or according to the new medical prescription.
Study: NCT01149044

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Coronary Intervention with or without manual aspiration thrombectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Coronary Intervention with or without manual aspiration thrombectomy